Why Did BSX Cut FY26 Guidance? CEO Details Three Unanticipated Factors At Bernstein Conference
Boston Scientific (BSX) shares fell 10% after CEO Mike Mahoney cited three factors for cutting FY26 guidance: slowdown in WATCHMAN business, market-share reduction in electrophysiology, and softness in urology. Stifel lowered its price target to $75. BSX is down 45% YTD.
How this was made
The 30-second read
Why it matters
The guidance cut is a primary disclosure that materially changes growth expectations, prompting a >10% share decline.
Market read
The new guidance revision is a significant catalyst for BSX and may influence related med‑tech stocks.
What to watch
Potential upside from upcoming product refreshes in the stone portfolio and continued R&D spend.
Background
Boston Scientific announced a FY26 guidance cut at a Bernstein conference, citing slower growth in WATCHMAN, EP competition, and urology softness.
Ticker impact
Boston Scientific cut FY26 net‑sales guidance to 7‑8.5% (reported) after CEO explained three unanticipated factors, causing a >10% share drop.
Potential further downside of 5‑10% over the next week as investors reassess growth outlook.
The guidance cut is a fresh, material disclosure for a large‑cap med‑tech firm, accompanied by a sharp price move, indicating strong market reaction.
Market effects
May weigh on med‑tech peers, especially those with exposure to electrophysiology and urology segments.
U.S. healthcare sector could see modest pressure in the near term.
Limited to investors tracking U.S. med‑tech equities; no broader macro effect.
Counterpoint
If the slowdown is temporary, the stock could rebound on the back of strong R&D pipeline and venture fund strength.
Key entities
- ExecutiveMike Mahoney
CEO of Boston Scientific providing the guidance update.
- AnalystStifel
Lowered price target to $75 from $85.
